NCT04132505 2026-04-06
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
11 trialsNCT03374254 2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04800822 2024-10-22
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT02613650 2024-08-09
A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
University of Utah
Phase 1 Completed
NCT04044430 2023-01-09
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
University of California, San Francisco
Phase 1 Terminated
NCT02510001 2021-07-13
MErCuRIC1
University of Oxford
Phase 1 Completed
NCT03158103 2021-04-30
A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01337765 2020-10-09
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Pfizer
Phase 1 Completed
NCT01363232 2020-10-05
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Array BioPharma
Phase 1 Completed
NCT00959127 2020-09-16
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed
NCT02041481 2018-01-25
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed